Royalty Pharma (RPRX) Income from Non-Controlling Interests (2019 - 2026)

Royalty Pharma has disclosed Income from Non-Controlling Interests across 8 years of filings, most recently posting $63.6 million for Q2 2026.

• In Q2 2026, Income from Non-Controlling Interests rose 5.2% year-over-year to $63.6 million; the TTM figure through Jun 2026 stood at $534.9 million (down 16.95% YoY), while the FY2025 annual figure was $553.2 million, up 17.26% from the prior year.
• Income from Non-Controlling Interests came in at $63.6 million for Q2 2026 at Royalty Pharma, down from $173.6 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $262.4 million in Q3 2024 to a low of -$153.9 million in Q4 2022.
• Average Income from Non-Controlling Interests over 5 years is $111.9 million, with a median of $124.9 million recorded in 2023.
• Year-over-year, Income from Non-Controlling Interests sank 436.37% in 2022 and jumped 2255.39% in 2025.
• Over 5 years, Income from Non-Controlling Interests stood at -$153.9 million in 2022, then jumped by 245.02% to $223.2 million in 2023, then sank by 43.5% to $126.1 million in 2024, then gained by 12.34% to $141.7 million in 2025, then plunged by 55.12% to $63.6 million in 2026.
• Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $63.6 million in Q2 2026, $173.6 million in Q1 2026, and $141.7 million in Q4 2025.